Small logo Subscribe to leading news on impact investing. Learn More
The Brief Originals Dealflow Signals The Impact Alpha Impact Voices Podcasts Agents of Impact Open
What's Next Measure Better Investing in Racial Equity Beyond Aid Beyond Trade-offs Impact en las Americas New Revivalists Women Rising in India Operation Impact
Smarter Money Women Rising 2030 Finance Locavesting Inclusive Economy Regeneration Impact Tech New Power Geographies
Slack Conference Calls Events Contribute
The Archive ImpactSpace The Accelerator Selection Tool Network Map
About Us FAQ Calendar Pricing and Payment Policy Privacy Policy Terms of Service Agreement Contact Us
Industry News Impact Management Good Business Personal Finance Faith and investing Billionaires
Gender Lens Investing Women Rising in India
SDGs Climate Finance Clean Energy Innovative Finance Full Stack Capital Long-termism
Opportunity Zones Investing in place
Entrepreneurship Return on Inclusion Good Jobs Inclusive Fintech Creative economy Housing New Schooled Well Being People on the Move
Conservation Finance Farmer Finance Financing Fish
Blockchain/AI/IoT Urban Tech Food Tech Inclusive Fintech
Human Rights Democracy and Peace News and Information
Africa Asia Europe Latin America Middle East Oceania/Australia China Canada India United Kingdom United States Growth Markets
Subscribe
Features
Series
Themes
Community
Data
Subscribe Log In
More

Japan’s Dai-ichi Life backs biotech venture Molcure



ImpactAlpha, December 3 – Tokyo-based Molcure is developing a machine learning-powered platform to support faster drug development and the discovery of new treatments for cancers and other diseases for which there are currently no effective treatments. Life insurance company Dai-ichi is investing ¥100 million ($880,000) in the five-year-old venture.

Molcure’s platform relies on artificial intelligence and machine learning to analyze genetic materials and quickly and more cost effectively identify potential antibodies for new drug treatments. Antibody drugs target specific cells in the body, minimizing treatment side-effects. The standard process for developing these treatments is time consuming: it can take six months to identify 20,000 antibody candidates, compared to Molcure’s method of analyzing 10 million candidates in one third of the time, according to a Dai-ichi statement.

Molcure is Dai-ichi’s seventh investment since launching its impact investing initiative last October. The ¥36.3 trillion ($319.9 billion) life insurance firm has primarily backed startups working on global health initiatives, like Molcure, and access to financial services, like microfinance company Gojo & Company.

Impact investing in Japan has seen rapid growth in recent years, doubling from $337 million to $718 million since 2016.

You might also like...